Two lots of Daytrana recalled
ADHD patch recalled due to liner failure.
Two lots of methylphenidate transdermal system (Daytrana, Shire) have failed to meet their release liner removal specification, leading to a voluntary recall by the manufacturer. Both lots 2750211 and 2764111 are affected and may cause difficulty removing the liners for both patients and caregivers, but do not pose any safety concerns, according to the company. Shire said it will continue to perform quality assurance monitoring to ensure no new cases of liner failure occur and that current supply levels of the patch should be sufficient despite the recall. Pharmacists with questions should direct them to the Daytrana customer service line at 1-(888)-879-8218.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
